Benefits of precision medicine in lung cancer: experience from a single institution

Abstract

Lung cancer remains the leading cause of cancer death worldwide and in China. Over the past two decades, targeted therapy and immunotherapy have improved the five-year survival rate of lung cancer, and precision medicine has played a great part in this progress. However, owing to the heterogeneity, complexity, and economic disparity, the usage of precision medicine is still low, which generally results in a poor prognosis. In view of the current bottlenecks, such as low early diagnosis rates and the poor prognosis of lung cancer patients, our team predicted and identified early diagnosis markers of lung cancer. We have described the genetic characteristics of lung cancer patients, identified potential treatment targets, and explored accurate treatment schemes for the disease. We have also promoted their application by conducting bioinformatic analysis, high-throughput sequencing, liquid biopsy, and improved FISH and other technologies. This has formed an integrated system for the precise diagnosis, treatment, and transformation of lung cancer research, obtaining good social benefits after their application.